Vaxcyte Phase 3 pneumococcal vaccine succeeds, challenging Pfizer and Merck

Vaxcyte announced its experimental pneumococcal vaccine met primary endpoints in a Phase 3 trial, positioning it to enter a market dominated by Pfizer and Merck. The result is a company-specific clinical milestone, not yet a regulatory approval or market launch. It signals potential competitive disruption in the lucrative vaccine segment, but commercial impact remains uncertain pending further data and regulatory review.